Tolterodine-pilocarpine combo eases dry mouth in patients with overactive bladder
The combination of tolterodine 2 mg and pilocarpine 9 mg relieves dry mouth in patients with overactive bladder while maintaining anticholinergic efficacy similar to that of tolterodine alone, a study has shown.
From baseline to 12 weeks, the mean change in the number of daily micturitions was –1.49 in the combination group and –1.74 in the tolterodine monotherapy group, with a mean difference of –0.26 (95 percent CI, –0.79 to 0.27), confirming noninferiority.
The combination group also had a lower incidence of dry mouth at 12 weeks than the tolterodine monotherapy group (30.0 percent vs 42.9 percent; p=0.009). Each group showed improvements in all secondary and other efficacy outcomes associated with overactive bladder symptoms, with no significant between-group differences at 12 weeks.
In addition, the combination group had significantly lower scores on the total xerostomia inventory and the visual analogue scale for dry mouth than the tolterodine monotherapy group.
Patients with overactive bladder symptoms were enrolled in this multicentre, randomized, double-blind, parallel, active control study. They were randomly assigned to receive either the combination or the 2-mg tolterodine twice daily for 12 weeks. All patients initiated the combination for 12 weeks after the double-blind period was completed.
The change from baseline in the mean number of daily micturitions and cumulative incidence of dry mouth at the end of 12 weeks were the primary endpoints. Secondary endpoints included other overactive bladder symptoms, total xerostomia inventory score, and results of a visual analogue scale for dry mouth at the end of 12 and 24 weeks.